Safety and efficacy of fingolimod in clinical practice: The experience of an academic center in the Middle East
- 1 December 2015
- journal article
- research article
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 289, 93-97
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Use of Fingolimod in the Management of Relapsing–Remitting Multiple Sclerosis: Experience from Latin AmericaAdvances in Therapy, 2015
- Real-World Use of Fingolimod in Patients with Relapsing Remitting Multiple Sclerosis: A Retrospective Study Using the National Multiple Sclerosis Registry in KuwaitCNS Drugs, 2014
- Relapse Rates in Patients with Multiple Sclerosis Switching from Interferon to Fingolimod or Glatiramer Acetate: A US Claims Database StudyPLOS ONE, 2014
- Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trialThe Lancet Neurology, 2012
- Evolving expectations around early management of multiple sclerosisTherapeutic Advances in Neurological Disorders, 2010
- Mechanism of Action of Oral Fingolimod (FTY720) in Multiple SclerosisClinical Neuropharmacology, 2010
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trialThe Lancet, 2009
- Clinically isolated syndrome: the rationale for early treatmentNature Clinical Practice Neurology, 2008
- Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised studyThe Lancet, 2001